2017. ISPOR Annual International Meeting – Importance of clinical outcome assessment (COA) data in the evaluation of medicines for the treatment of Alzheimer’s Disease (AD): A review of the labels of medicines approved by the FDA and the EMA

Perrier LL, Emery MP, Anfray C, Acquadro C. Importance of clinical outcome assessment (COA) data in the evaluation of medicines for the treatment of Alzheimer’s Disease (AD): A review of the labels of medicines approved by the FDA and the EMA. Value Health. 2017 May;20(5):A342-A343. Presented at: ISPOR 22nd Annual International Meeting; May 24, 2017; Boston, MA, USA.